186 related articles for article (PubMed ID: 17592750)
21. Osteopontin is elevated in Parkinson's disease and its absence leads to reduced neurodegeneration in the MPTP model.
Maetzler W; Berg D; Schalamberidze N; Melms A; Schott K; Mueller JC; Liaw L; Gasser T; Nitsch C
Neurobiol Dis; 2007 Mar; 25(3):473-82. PubMed ID: 17188882
[TBL] [Abstract][Full Text] [Related]
22. The isolation of neural stem cells from the olfactory bulb of Parkinson's disease model.
Hayakawa H; Hayashita-Kinoh H; Nihira T; Seki T; Mizuno Y; Mochizuki H
Neurosci Res; 2007 Mar; 57(3):393-8. PubMed ID: 17222932
[TBL] [Abstract][Full Text] [Related]
23. Correlation between levels of pigment epithelium-derived factor and vascular endothelial growth factor in the striatum of patients with Parkinson's disease.
Yasuda T; Fukuda-Tani M; Nihira T; Wada K; Hattori N; Mizuno Y; Mochizuki H
Exp Neurol; 2007 Aug; 206(2):308-17. PubMed ID: 17604022
[TBL] [Abstract][Full Text] [Related]
24. Effects of levodopa on striatal monoamines in mice with levodopa-induced hyperactivity.
Nicholas AP; Buck K; Ferger B
Neurosci Lett; 2008 Oct; 443(3):204-8. PubMed ID: 18657593
[TBL] [Abstract][Full Text] [Related]
25. Melatonin and its brain metabolite N(1)-acetyl-5-methoxykynuramine prevent mitochondrial nitric oxide synthase induction in parkinsonian mice.
Tapias V; Escames G; López LC; López A; Camacho E; Carrión MD; Entrena A; Gallo MA; Espinosa A; Acuña-Castroviejo D
J Neurosci Res; 2009 Oct; 87(13):3002-10. PubMed ID: 19437546
[TBL] [Abstract][Full Text] [Related]
26. Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration.
McGeer PL; Schwab C; Parent A; Doudet D
Ann Neurol; 2003 Nov; 54(5):599-604. PubMed ID: 14595649
[TBL] [Abstract][Full Text] [Related]
27. Nigral neurodegeneration triggered by striatal AdIL-1 administration can be exacerbated by systemic IL-1 expression.
Pott Godoy MC; Ferrari CC; Pitossi FJ
J Neuroimmunol; 2010 May; 222(1-2):29-39. PubMed ID: 20350768
[TBL] [Abstract][Full Text] [Related]
28. Validity of the MPTP-Treated Mouse as a Model for Parkinson's Disease.
Klemann CJHM; Martens GJM; Poelmans G; Visser JE
Mol Neurobiol; 2016 Apr; 53(3):1625-1636. PubMed ID: 25676140
[TBL] [Abstract][Full Text] [Related]
29. Broad neuroprotective profile of nicotinamide in different mouse models of MPTP-induced parkinsonism.
Anderson DW; Bradbury KA; Schneider JS
Eur J Neurosci; 2008 Aug; 28(3):610-7. PubMed ID: 18702732
[TBL] [Abstract][Full Text] [Related]
30. Human neuromelanin induces neuroinflammation and neurodegeneration in the rat substantia nigra: implications for Parkinson's disease.
Zecca L; Wilms H; Geick S; Claasen JH; Brandenburg LO; Holzknecht C; Panizza ML; Zucca FA; Deuschl G; Sievers J; Lucius R
Acta Neuropathol; 2008 Jul; 116(1):47-55. PubMed ID: 18343932
[TBL] [Abstract][Full Text] [Related]
31. Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study.
Shin JY; Park HJ; Ahn YH; Lee PH
J Neurochem; 2009 Nov; 111(4):1042-50. PubMed ID: 19765187
[TBL] [Abstract][Full Text] [Related]
32. NLRP3 inflammasome pathway is involved in olfactory bulb pathological alteration induced by MPTP.
Chen Y; Zhang QS; Shao QH; Wang S; Yuan YH; Chen NH; Wang HB
Acta Pharmacol Sin; 2019 Aug; 40(8):991-998. PubMed ID: 30728466
[TBL] [Abstract][Full Text] [Related]
33. RANTES-induced invasion of Th17 cells into substantia nigra potentiates dopaminergic cell loss in MPTP mouse model of Parkinson's disease.
Dutta D; Kundu M; Mondal S; Roy A; Ruehl S; Hall DA; Pahan K
Neurobiol Dis; 2019 Dec; 132():104575. PubMed ID: 31445159
[TBL] [Abstract][Full Text] [Related]
34. Neurotoxicity of MPTP to migrating neuroblasts: studies in acute and subacute mouse models of Parkinson's disease.
He XJ; Yamauchi H; Uetsuka K; Nakayama H
Neurotoxicology; 2008 May; 29(3):413-20. PubMed ID: 18387672
[TBL] [Abstract][Full Text] [Related]
35. Risk is in the air: an intranasal MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) rat model of Parkinson's disease.
Prediger RD; Rial D; Medeiros R; Figueiredo CP; Doty RL; Takahashi RN
Ann N Y Acad Sci; 2009 Jul; 1170():629-36. PubMed ID: 19686204
[TBL] [Abstract][Full Text] [Related]
36. Metabolic changes detected by proton magnetic resonance spectroscopy in vivo and in vitro in a murin model of Parkinson's disease, the MPTP-intoxicated mouse.
Chassain C; Bielicki G; Durand E; Lolignier S; Essafi F; Traoré A; Durif F
J Neurochem; 2008 May; 105(3):874-82. PubMed ID: 18088356
[TBL] [Abstract][Full Text] [Related]
37. Tripchlorolide protects against MPTP-induced neurotoxicity in C57BL/6 mice.
Hong Z; Wang G; Gu J; Pan J; Bai L; Zhang S; Chen SD
Eur J Neurosci; 2007 Sep; 26(6):1500-8. PubMed ID: 17714494
[TBL] [Abstract][Full Text] [Related]
38. 6-hydroxydopamine-induced Parkinson's disease-like degeneration generates acute microgliosis and astrogliosis in the nigrostriatal system but no bioluminescence imaging-detectable alteration in adult neurogenesis.
Fricke IB; Viel T; Worlitzer MM; Collmann FM; Vrachimis A; Faust A; Wachsmuth L; Faber C; Dollé F; Kuhlmann MT; Schäfers K; Hermann S; Schwamborn JC; Jacobs AH
Eur J Neurosci; 2016 May; 43(10):1352-65. PubMed ID: 26950181
[TBL] [Abstract][Full Text] [Related]
39. Differences between subacute and chronic MPTP mice models: investigation of dopaminergic neuronal degeneration and alpha-synuclein inclusions.
Gibrat C; Saint-Pierre M; Bousquet M; Lévesque D; Rouillard C; Cicchetti F
J Neurochem; 2009 Jun; 109(5):1469-82. PubMed ID: 19457163
[TBL] [Abstract][Full Text] [Related]
40. Bak Foong protects dopaminergic neurons against MPTP-induced neurotoxicity by its anti-apoptotic activity.
Liu B; Xie JX; Tsang LL; Rowlands DK; Ho LS; Gou YL; Chung YW; Chan HC
Cell Biol Int; 2008 Jan; 32(1):86-92. PubMed ID: 17920944
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
